Compare Stocks: SLS, KRYS, KYMR, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$324.55 +1.0%	$337.56	$184.02 ▼ $382.54	$9.51B	0.5	271,396 shs	190,766 shs
KYMR Kymera Therapeutics	$122.60 +0.1%	$114.83	$55.66 ▼ $130.05	$10.19B	1.98	831,641 shs	1.05 million shs
SLS SELLAS Life Sciences Group	$10.15 -2.2%	$12.23	$1.39 ▼ $15.88	$2.10B	2.56	6.51 million shs	8.32 million shs
SYRE Spyre Therapeutics	$98.96 -0.8%	$90.28	$21.15 ▼ $110.18	$10.17B	3.1	1.40 million shs	567,635 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	+0.97%	+1.38%	-3.14%	-4.86%	+75.39%
KYMR Kymera Therapeutics	+0.07%	+10.60%	+10.94%	+18.57%	+104.23%
SLS SELLAS Life Sciences Group	-2.22%	-10.57%	-11.82%	+1.40%	+387.98%
SYRE Spyre Therapeutics	-0.79%	+7.18%	+16.81%	+0.64%	+315.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$324.55 +1.0%	$337.56	$184.02 ▼ $382.54	$9.51B	0.5	271,396 shs	190,766 shs
KYMR Kymera Therapeutics	$122.60 +0.1%	$114.83	$55.66 ▼ $130.05	$10.19B	1.98	831,641 shs	1.05 million shs
SLS SELLAS Life Sciences Group	$10.15 -2.2%	$12.23	$1.39 ▼ $15.88	$2.10B	2.56	6.51 million shs	8.32 million shs
SYRE Spyre Therapeutics	$98.96 -0.8%	$90.28	$21.15 ▼ $110.18	$10.17B	3.1	1.40 million shs	567,635 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	+0.97%	+1.38%	-3.14%	-4.86%	+75.39%
KYMR Kymera Therapeutics	+0.07%	+10.60%	+10.94%	+18.57%	+104.23%
SLS SELLAS Life Sciences Group	-2.22%	-10.57%	-11.82%	+1.40%	+387.98%
SYRE Spyre Therapeutics	-0.79%	+7.18%	+16.81%	+0.64%	+315.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	2.93	Moderate Buy	$377.20	16.22% Upside
KYMR Kymera Therapeutics	2.89	Moderate Buy	$137.32	12.01% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-1.48% Downside
SYRE Spyre Therapeutics	2.94	Moderate Buy	$110.40	11.56% Upside

Current Analyst Ratings Breakdown

Latest SLS, KRYS, KYMR, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$140.00
10/29/2026	KYMR Kymera Therapeutics	Loop Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$132.00
10/29/2026	KYMR Kymera Therapeutics	Brookline Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/29/2026	KYMR Kymera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/29/2026	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$134.00 ➝ $139.00
10/27/2026	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$135.00 ➝ $146.00
10/23/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/23/2026	KRYS Krystal Biotech	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/19/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$121.00
10/15/2026	KYMR Kymera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SLS SELLAS Life Sciences Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$440.48M	21.81	$7.36 per share	44.09	$42.06 per share	7.72
KYMR Kymera Therapeutics	$39.21M	259.99	N/A	N/A	$19.42 per share	6.31
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A
SYRE Spyre Therapeutics	$890K	11,331.48	N/A	N/A	$7.21 per share	13.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$204.83M	$7.98	40.67	36.96	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	N/A
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/18/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest SLS, KRYS, KYMR, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/18/2026	Q3 2026	SLS SELLAS Life Sciences Group	-$0.05	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7807	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.79	N/A	N/A	N/A	$125.77 million	N/A
10/29/2026	Q3 2026	KYMR Kymera Therapeutics	-$1.26	-$1.32	-$0.06	-$1.32	$3.28 million	$1.35 million
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	8.32	7.96
KYMR Kymera Therapeutics	N/A	10.34	10.34
SLS SELLAS Life Sciences Group	N/A	18.83	18.83
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
KYMR Kymera Therapeutics	N/A
SLS SELLAS Life Sciences Group	17.38%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.10%
KYMR Kymera Therapeutics	15.98%
SLS SELLAS Life Sciences Group	1.30%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable

SLS, KRYS, KYMR, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics (SYRE) Projected to Release Quarterly Earnings on Tuesday

October 27 at 8:40 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Share Price Breaks Above Fifty Day Moving Average - Should You Sell?

October 27 at 4:59 AM | marketbeat.com

Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview

October 23, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Given Buy Rating at BTIG Research

October 19, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - What's Next?

October 19, 2026 | marketbeat.com

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

October 18, 2026 | globenewswire.com

Assenagon Asset Management S.A. Makes New $53.35 Million Investment in Spyre Therapeutics, Inc. $SYRE

October 18, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by UBS Group

October 14, 2026 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Target Price of $109.71 According to Analysts

October 10, 2026 | marketbeat.com

Spyre Therapeutics Announces $350 Million Public Stock Offering Priced at $85 Per Share

October 9, 2026 | kalkinemedia.comK

Spyre Therapeutics (NASDAQ:SYRE) Stock Jumps 7.3% - Here's What Happened

October 9, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering

October 8, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - October 5, 2026

October 6, 2026 | biospace.comB

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Falls 12.7% - Should You Sell?

October 6, 2026 | marketbeat.com

Spyre Therapeutics Prices $350 Mln Public Offering Of Shares

October 6, 2026 | rttnews.com

Spyre Therapeutics prices $350M public offering at $85 per share

October 6, 2026 | msn.com

Spyre Therapeutics Commences Public Offering of Common Stock

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics stock falls on public offering launch

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, KRYS, KYMR, and SYRE Company Descriptions

Krystal Biotech NASDAQ:KRYS

$324.55 +3.13 (+0.97%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$323.02 -1.54 (-0.47%)

As of 10/29/2026 07:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Kymera Therapeutics NASDAQ:KYMR

$122.60 +0.09 (+0.07%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$122.58 -0.02 (-0.02%)

As of 10/29/2026 07:30 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

SELLAS Life Sciences Group NASDAQ:SLS

$10.15 -0.23 (-2.22%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$10.06 -0.09 (-0.89%)

As of 05:03 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Spyre Therapeutics NASDAQ:SYRE

$98.96 -0.79 (-0.79%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$98.96 0.00 (0.00%)

As of 10/29/2026 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KRYS, KYMR, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KRYS, KYMR, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KRYS, KYMR, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, KRYS, KYMR, and SYRE Company Descriptions

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

SELLAS Life Sciences Group NASDAQ:SLS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KRYS, KYMR, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KRYS, KYMR, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KRYS, KYMR, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, KRYS, KYMR, and SYRE Company Descriptions

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

SELLAS Life Sciences Group NASDAQ:SLS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools